Crohn's disease and ulcerative colitis are the two major types of inflammatory bowel disease, and affect mainly the gastrointestinal tract but also have extraintestinal sequelae, such as arterial and venous thromboembolism. Thromboembolic complications, particularly pulmonary thromboembolism, can be life threatening and require prompt management with anticoagulants. Conventional vitamin K antagonists have been used for the treatment of thromboembolic complications, but the development of novel oral anticoagulants has shifted the paradigm. We report a case of a 42-year-old female with ulcerative colitis who experienced an acute flare-up due to cytomegalovirus superinfection with pulmonary thromboembolism. She was treated with oral mesalamine, intravenous steroid and ganciclovir and low-molecular-weight heparin, followed by rivaroxaban, a novel oral anticoagulant. Her symptoms resolved after treatment, and no recurrence was noted during a 6-month post-treatment follow-up. (Korean J Gastroenterol 2017;70:44-49) 
INTRODUCTION
Crohn's disease (CD) and ulcerative colitis (UC) are the two major types of inflammatory bowel disease (IBD), which affect mainly the gastrointestinal tract, but can also exhibit extraintestinal involvement, such as arterial and venous thromboembolism. 1 Although arterial and venous thromboembolism can be devastating to IBD patients, they are frequently overlooked by physicians. 2 The mainstay of therapy for thromboembolism is anticoagulation, and vitamin K antagonists (VKAs) are frequently used as the standard treatment. 3 The recently developed novel oral anticoagulants (NOACs) may replace VKAs in thromboembolic treatment. [3] [4] [5] [6] However, no report of treatment of UC with thromboembolism using NOACs has been reported to date, and treatment guidelines have not been established. 2, 7 We report here a case of a patient with severe acute UC, deep vein thrombosis and pulmonary thromboembolism, together with cytomegalovirus colitis, who was successfully treated using the NOAC rivaroxaban. 
CASE REPORT
A 42-year-old female patient presented to the clinic with complaints of fever and chest discomfort of 1-week duration.
She had been diagnosed with UC pancolitis 4 years prior and treated with oral mesalamine and episodic oral steroid. antibody, protein C and S activity, homocysteine and complement levels were within the normal range.
Initial sigmoidoscopy revealed multiple longitudinal ulcerations with a friable mucosa and easy touch bleeding in all colonic fields ( the left common iliac vein to the calf veins of the lower left leg and filling defects in the lobar and segmental branches of the right lung, suggesting pulmonary thromboembolism (Fig. 2, 3 ).
We started oral mesalamine and azathioprine and intravenous hydrocortisone and then switched to oral prednisolone as management for severe acute UC. Ganciclovir 5 mg/kg bid was administered for CMV colitis, and low-molecular-weight heparin for 2 weeks was given for pulmonary thromboembolism, followed by a switch to oral rivaroxaban.
There are many data supporting the efficacy in patient treat- For the pulmonary thromboembolism, chest discomfort subsided on day 3 of hospitalization, and the left leg swelling and pain subsided on day 6 of hospitalization. The patient was discharged on day 40 of hospitalization without complications.
After rivaroxaban treatment for 2 months, a follow-up chest CT was performed (Fig. 4) . and CD show a threefold higher incidence of thrombosis, and up to a 16-fold increase during disease flare-ups. 8 A study in an Asian population reported 1.98-and 1.80-fold increases in the incidence of DVT and PTE, respectively. 9 In the general population, the 30-day case fatality rates of DVT and PTE are 11-30%, 10, 11 and these data also correlate with IBD patients which can be life threatening. 12 Therefore, prompt management is necessary to reduce the morbidity and mortality of these patients. Thromboembolism is caused by changes in the composition of the blood, stasis of the blood, and changes in the vessel wall, as postulated by Virchow. 9 In IBD patients, localized and systemic inflammation can activate the coagulation cascade, resulting in increased levels of coagulation factors (such as fibrinogen, thrombocytes, factor V, and factor VIII) and decreased levels of inhibitors of blood clotting activation (such as antithrombin and protein C and S). 13 These changes promote hypercoagulability in IBD patients, which in turn increases the risk of DVT and PTE.
An association between CMV infection and thromboembo- 17 However, VKAs increase the risk of major bleeding events by 1.6-2.6% and the case-fatality rate by 11.0% during the 6 months of venous thromboembolism treatment. 4 Therefore, the INR should be monitored. Use of NOACs abolishes the need to monitor the INR, with similar efficacy and a lower incidence of bleeding complications.
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The patient's body mass index was 14.0 and her peripheral veins were very vulnerable that every time we gave injections or took blood samples, the patient suffered great pain. The use of rivaroxaban in place of conventional treatment with
VKAs yielded an excellent outcome with no complications, and the decreased frequency of blood draws satisfied the patient.
Many cases of pulmonary thromboembolism in IBD patients have been reported, 18, 19 but none has involved the use of NOACs, with the exception of one case of cerebral venous thrombosis in CD. 20 Our patient was treated with rivaroxaban for 6 months and did not experience recurrence during that time. We believe that in the near future, NOACs should replace VKAs for treatment of thrombotic complications in IBD patients.
